☰

Alan Friedman - Publications

Affiliations: 
University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Modern Literature, American Literature, English Literature
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Fleischmann R, Friedman A, Drescher E, Singhal A, Cortes-Maisonet G, Doan T, Lu W, Wang Z, Nader A, Housley W, Cohen S, Taylor PC, Blanco R. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. The Lancet. Rheumatology. 4: e395-e406. PMID 38293957 DOI: 10.1016/S2665-9913(22)00092-3  0.301
2020 Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford, England). PMID 33313898 DOI: 10.1093/rheumatology/keaa770  0.306
2020 Edwards CJ, Sawant R, Garg V, Du EX, Friedman A, Betts KA. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy. PMID 33244703 DOI: 10.1007/s40744-020-00257-w  0.306
2020 Takeuchi T, Rischmueller M, Blanco R, Xavier RM, Ueki Y, Atsumi T, Chen S, Friedman A, Pangan AL, Strand V, van Vollenhoven RF. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: A sub-analysis of the Phase 3 SELECT-EARLY study. Modern Rheumatology. 1-22. PMID 33164611 DOI: 10.1080/14397595.2020.1847776  0.302
2020 van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, Rischmueller M, Blanco R, Xavier RM, Strand V. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial. Arthritis & Rheumatology (Hoboken, N.J.). PMID 32638504 DOI: 10.1002/Art.41384  0.413
2020 Peterfy C, Strand V, Genovese MC, Friedman A, Enejosa JJ, Hall S, Mysler E, Durez P, Baraliakos X, Shaw T, Song Y, Li Y, Song IH. Thu0211 Radiographic Outcomes In Patients With Rheumatoid Arthritis Receiving Upadacitinib As Monotherapy Or In Combination With Methotrexate: Results At 2 Years From The Select-Compare And Select-Early Studies Annals of the Rheumatic Diseases. 79: 330-331. DOI: 10.1136/Annrheumdis-2020-Eular.1869  0.437
2020 Vollenhoven RV, Takeuchi T, Rischmueller M, Blanco R, Xavier R, Howard M, Friedman A, Song Y, Strand V. Thu0217 Upadacitinib Monotherapy In Methotrexate-Naïve Patients With Rheumatoid Arthritis: Results At 72 Weeks From Select-Early Annals of the Rheumatic Diseases. 79: 334-335. DOI: 10.1136/Annrheumdis-2020-Eular.1857  0.409
2020 Kapetanovic MC, Andersson M, Friedman A, Shaw T, Song Y, Aletaha D, Buch MH, Müller-Ladner U, Pope J. Sat0145 Efficacy And Safety Of Upadacitinib Monotherapy In Mtx-Naïve Patients With Early Active Ra Receiving Treatment Within 3 Months Of Diagnosis: A Post-Hoc Analysis Of The Select-Early Annals of the Rheumatic Diseases. 79: 1011-1011. DOI: 10.1136/Annrheumdis-2020-Eular.1431  0.433
2020 Peterfy C, Genovese MC, Song I, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JJ, Shaw T, Li Y, Chen S, Strand V. P225 Inhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patrients with RA: one-year outcomes from the select Phase 3 programme Rheumatology. 59. DOI: 10.1093/Rheumatology/Keaa111.220  0.353
2020 Edwards C, Sawant R, Du EX, Cammarota J, Tang P, Garg V, Friedman A, Betts K. P224 A matching-adjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csDMARD-IR patients with moderate to severe RA Rheumatology. 59. DOI: 10.1093/Rheumatology/Keaa111.219  0.375
2020 Hall S, Takeuchi T, Thomson G, Emery P, Combe B, Everding A, Pavelka K, Song Y, Shaw T, Friedman A, Song I, Mysler E. P200 Characterisation of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators Rheumatology. 59. DOI: 10.1093/Rheumatology/Keaa111.195  0.381
2019 Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Research & Therapy. 21: 272. PMID 31815649 DOI: 10.1186/S13075-019-2037-1  0.391
2019 Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Research & Therapy. 21: 263. PMID 31791386 DOI: 10.1186/S13075-019-2059-8  0.436
2019 Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet (London, England). PMID 31130260 DOI: 10.1016/S0140-6736(19)30419-2  0.421
2019 Strand V, Tundia N, Radominski S, Friedman A, Dunlap K, Goldschmidt D, Bergman M. Thu0192 Upadacitinib Monotherapy Improves Patient-Reported Outcomes In Methotrexate-Naïve Patients With Moderately To Severely Active Rheumatoid Arthritis: Results From Select-Early Annals of the Rheumatic Diseases. 78: 372-373. DOI: 10.1136/Annrheumdis-2019-Eular.978  0.445
2019 Edwards C, Sawant R, Du E, Cammarota J, Tang P, Garg V, Friedman A, Betts K. Thu0168 A Matching-Adjusted Indirect Comparison (Maic) Of Upadacitinib Versus Tofacitinib In Csdmard-Ir Patients With Moderate To Severe Rheumatoid Arthritis (Ra) Annals of the Rheumatic Diseases. 78: 358-358. DOI: 10.1136/Annrheumdis-2019-Eular.7189  0.436
2019 Vollenhoven Rv, Takeuchi T, Pangan A, Friedman A, Chen S, Rischmueller M, Blanco R, Xavier R, Strand V. Thu0197 Monotherapy With Upadacitinib In Mtx-Naïve Patients With Rheumatoid Arthritis: Results At 48 Weeks From The Select-Early Study Annals of the Rheumatic Diseases. 78: 376-377. DOI: 10.1136/Annrheumdis-2019-Eular.3350  0.337
2019 Burmester GR, Bosch Fvd, Bessette L, Kivitz A, Yihan L, Friedman A, Pangan A, Camp H, Kremer J. Fri0132 Long-Term Safety And Efficacy Of Upadacitinib In Patients With Rheumatoid Arthritis And An Inadequate Response To Csdmards: Results At 60 Weeks From The Select-Next Study Annals of the Rheumatic Diseases. 78: 735-736. DOI: 10.1136/Annrheumdis-2019-Eular.3082  0.436
2019 Peterfy C, Genovese MC, Song I, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JJ, Shaw T, Yihan L, Chen S, Strand V. Thu0188 Inhibition Of Structural Joint Damage With Upadacitinib As Monotherapy Or In Combination With Methotrexate In Patients With Rheumatoid Arthritis: 1 Year Outcomes From The Select Phase 3 Program Annals of the Rheumatic Diseases. 78: 369-370. DOI: 10.1136/Annrheumdis-2019-Eular.2871  0.429
2019 Hall S, Takeuchi T, Thomson G, Emery P, Combe B, Everding A, Pavelka K, Song Y, Shaw T, Friedman A, Song I, Mysler E. Thu0174 Characterization Of Remission In Patients With Rheumatoid Arthritis Treated With Upadacitinib Or Comparators Annals of the Rheumatic Diseases. 78: 362-362. DOI: 10.1136/Annrheumdis-2019-Eular.2003  0.312
2019 Smolen JS, Cohen S, Emery P, Rigby W, Tanaka Y, Zhang Y, Friedman A, Othman AA, Camp HS, Pangan AL. 060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate Rheumatology. 58. DOI: 10.1093/Rheumatology/Kez106.059  0.398
2019 Vollenhoven Rv, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, Rischmueller M, Blanco R, Xavier RM, Strand V. 059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis Rheumatology. 58. DOI: 10.1093/Rheumatology/Kez106.058  0.403
2018 Genovese MC, Kremer J, Zhong S, Friedman A. SAT0236 Long-term safety and efficacy of upadacitinib (ABT-494), an oral jak-1 inhibitor in patients with rheumatoid arthritis in an open label extension study Annals of the Rheumatic Diseases. 77: 979-979. DOI: 10.1136/Annrheumdis-2018-Eular.7021  0.408
2018 Smolen J, Cohen S, Emery P, Rigby W, Tanaka Y, Zhang Y, Friedman A, Othman A, Camp H, Pangan A. OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate Annals of the Rheumatic Diseases. 77: 67-68. DOI: 10.1136/Annrheumdis-2018-Eular.4237  0.435
2018 Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J. SAT0255 Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND PHASE III TRIAL) Annals of the Rheumatic Diseases. 77: 990-990. DOI: 10.1136/Annrheumdis-2018-Eular.1254  0.435
2017 Strand V, Tundia N, Song I, Meerwein S, Lin J, Chen N, Friedman A. SAT0217 Early patient-reported outcomes and clinical outcomes with abt-494 in patients with active rheumatoid arthritis who are inadequate responders to methotrexate or tumor necrosis factor inhibitors: post-hoc analysis of phase 2 randomized controlled trials Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2017-Eular.1143  0.376
2016 Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC. A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy. Arthritis & Rheumatology (Hoboken, N.J.). PMID 27389975 DOI: 10.1002/Art.39801  0.398
2016 Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A. An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate and Apremilast in the Treatment of Methotrexate-naïve Patients with Psoriatic Arthritis. Current Medical Research and Opinion. 1-25. PMID 26743448 DOI: 10.1185/03007995.2016.1140026  0.36
2016 Kremer JM, Keystone EC, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Jungerwirth S. AB0390 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance To Anti-TNF Biologic Therapy Annals of the Rheumatic Diseases. 75: 1038-1039. DOI: 10.1136/Annrheumdis-2016-Eular.1448  0.435
2015 Kavanaugh A, Greenberg J, Reed G, Griffith J, Friedman A, Saunders K, Ganguli A. FRI0105 Benefit of Biologic Initiation in Moderate VS Severe Rheumatoid Arthritis: Evidence from a Real-World Registry Annals of the Rheumatic Diseases. 74: 457-458. DOI: 10.1136/Annrheumdis-2015-Eular.1182  0.413
Show low-probability matches.